ISTANBUL, Oct. 7 /PRNewswire/ -- Hizentra® (IgPro20) provides primary immunodeficiency (PI) patients with a safe and effective alternative to other immunoglobulin therapies when given in equivalent doses, according to Phase III pivotal trial data presented today at the XIVth Meeting of the European Society for Immunodeficiencies (ESID). Hizentra, the first and only 20 percent SCIg developed for subcutaneous (i.e., under the skin) administration, can be stored at room temperature over its entire 24-month shelf life given its formulation with L-proline.
